Andy Hsieh
Stock Analyst at William Blair
(0.04)
# 4,141
Out of 4,784 analysts
13
Total ratings
14.29%
Success rate
-27.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $5.52 | - | 1 | Feb 28, 2025 | |
SKYE Skye Bioscience | Initiates: Outperform | n/a | $1.87 | - | 1 | Feb 28, 2025 | |
ALT Altimmune | Initiates: Market Perform | n/a | $5.32 | - | 1 | Feb 28, 2025 | |
TERN Terns Pharmaceuticals | Initiates: Market Perform | n/a | $2.92 | - | 1 | Feb 28, 2025 | |
GPCR Structure Therapeutics | Initiates: Outperform | n/a | $19.77 | - | 1 | Feb 28, 2025 | |
BIOA BioAge Labs | Initiates: Market Perform | n/a | $3.82 | - | 1 | Feb 28, 2025 | |
MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $0.38 | - | 1 | Feb 6, 2025 | |
ELEV Elevation Oncology | Initiates: Outperform | n/a | $0.26 | - | 1 | Jan 3, 2025 | |
PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $1.06 | - | 1 | Nov 21, 2024 | |
LNTH Lantheus Holdings | Initiates: Outperform | n/a | $96.16 | - | 1 | Sep 29, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.31 | - | 2 | Jun 26, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.81 | - | 1 | Feb 21, 2023 |
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $5.52
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.87
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $5.32
Upside: -
Terns Pharmaceuticals
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $2.92
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $19.77
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $3.82
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.38
Upside: -
Elevation Oncology
Jan 3, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.26
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.06
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $96.16
Upside: -
Jun 26, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.81
Upside: -